A precision oncology clinical trial in the works at the OHSU Knight Cancer Institute gained a $25,000 pledge from Intel Corp. The company said it will contribute the money by means of a fund...
At the recent European Society for Medical Oncology meeting, OHSU oncologist Julie Graff, M.D., presented the first evidence of meaningful clinical activity for PD-1 blockade in men with...
The best available treatment for acute myeloid leukemia is a drug combination established more than 30 years ago. And today less than a third of newly diagnosed AML patients survive beyond five...
Nearly a third of people diagnosed with pancreatic adenocarcinoma have locally advanced tumors that cannot be removed by surgery. A longstanding and critical question for these patients is...